Smart risk tools to personalize NMIBC care
Episode 3. BCG, cystectomy, or other bladder-sparing treatment options? Ashish Kamat and Félix Guerrero-Ramos discuss how guideline-based risk stratification (EAU, IBCG) meets the realities of clinical practice. From intermediate-risk dilemmas to the nuances of BCG treatment duration and unresponsive disease, they explore how clinical choices shift when patient profiles and preferences enter the equation. Ramos shares his guiding principle: “You need to tailor the therapy to the patient, not just to the tumor.” Plus, he shares the one red flag that could change everything. View transcript.
Chapters
00:00 Welcome and introductions
00:39 Why stratify NMIBC patients?
03:32 Explaining treatment to patients
04:51 Treatment by risk category
06:00 Who needs cystectomy vs BCG?
10:08 Are molecular tools used today?
12:17 What defines BCG-unresponsive?
18:05 What if BCG no longer works?
19:55 What’s next for stratification?
21:13 Wrap-up
Meet the guest speaker
Félix Guerrero-Ramos, MD, PhD, FEBU
Félix Guerrero-Ramos is an attending urologist at Hospital Universitario 12 de Octubre in Madrid, Spain, where he coordinates the Urological Oncology section. He specializes in surgeries within urological oncology and has been the principal investigator for over 30 phase 1–4 clinical trials on bladder and renal cancer. He also collaborates as a Professor and Academic Tutor for final-year medical students at the Faculty of Medicine, Universidad Complutense de Madrid.
Disclosures: Research support / Principal Investigator for Astellas, AstraZeneca, Bristol Myers Squibb, Cepheid, Combat Medical, enGene, Fidia, Johnson & Johnson, MSD, Pfizer, Roche, Seagen, Taris, and UroGen. An employee of SERMAS (Servicio Madrileño de Salud). Consultant services for AstraZeneca, Bristol Myers Squibb, Combat Medical, enGene, Johnson & Johnson, Merck, MSD, Nanobots Therapeutics, Pfizer, Roche, and Taris. Stockholder in CG Oncology, Johnson & Johnson, and Pfizer. Speaker bureau for AstraZeneca, Bristol Myers Squibb, Combat Medical, Janssen, Johnson & Johnson, Merck, MSD, Nucleix, Pfizer, Palex, and Recordati. Travel support for Alter, AstraZeneca, Combat Medical, Fidia, Ipsen, Johnson & Johnson, Nucleix, Pfizer, Recordati, and Salvat. Member of scientific advisory boards for AstraZeneca, Bristol Myers Squibb, Combat Medical, enGene, Johnson & Johnson, MSD, Nucleix, Pfizer, Roche, and Taris. Manuscript support from AstraZeneca, Bristol Myers Squibb, Combat Medical, Janssen, Johnson & Johnson, and Pfizer.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.